Marc Küng

Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study

Fernando Rivera, Manuel Benavides, Javier Gállego et al. · Pancreatology · 2018 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Christoph Rochlitz, Martin Bigler, Roger von Moos et al. · BMC Cancer · 2016 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana et al. · Journal of Clinical Oncology · 2025 · 38 citations · Full text

Medicine, Oncology, Pharmacology +9

Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients

Christine Hohl Moinat, Daniel Périard, Adrienne Grueber et al. · Journal of Oncology · 2014 · 34 citations · Full text

Medicine, Oncology, Surgery +6

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

Christoph Rochlitz, Roger von Moos, Martin Bigler et al. · Journal of Clinical Oncology · 2014 · 14 citations

Medicine, Oncology, Pharmacology +17